Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker.
about
Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenograftsCurrent and emerging biomarkers of cell death in human disease.Cellular levels of oxidative stress affect the response of cervical cancer cells to chemotherapeutic agentsChemically synthesized CdSe quantum dots inhibit growth of human lung carcinoma cells via ROS generationDNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunityNovel serum proteomic signatures in a non-human primate model of retinal injuryAnalysis of the Rana catesbeiana tadpole tail fin proteome and phosphoproteome during T3-induced apoptosis: identification of a novel type I keratin.Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: a prospective study.E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancerLeptin signaling and apoptotic effects in human prostate cancer cell lines.Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead.Pharmacodynamic modelling of biomarker data in oncology.Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease.The human keratins: biology and pathology.A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumorsCdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluationCaspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy.Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitisBiomarker method validation in anticancer drug developmentThe Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-AnalysisAnnexin A1 contributes to pancreatic cancer cell phenotype, behaviour and metastatic potential independently of Formyl Peptide Receptor pathway.Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression.A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.The significance of caspase-cleaved cytokeratin 18 in pleural effusionTargeting cell death signaling in colorectal cancer: current strategies and future perspectives.Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.Serum efficacy biomarkers for oncology.Harnessing the cell death pathway for targeted cancer treatment.Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B.Loss of cell membrane integrity in puumala hantavirus-infected patients correlates with levels of epithelial cell apoptosis and perforin.Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells.Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cellsA quantitative real-time approach for discriminating apoptosis and necrosisDocetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C.The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.Elevated serum levels of cell death circulating biomarkers, M30 and M65, in patients with β-thalassemia major.Serum programmed cell death protein 5 (PDCD5) levels is upregulated in liver diseases.Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122.The clinical significance of apoptosis and M30 expression in colonic cancer progression.
P2860
Q27329087-146F01A1-E3D0-4A2A-8279-B77817488796Q27690667-72985C43-B828-41B8-84E6-1DFE3BBFA825Q28383284-92435C76-4831-4C94-A7A3-8DC05F6D453DQ28391109-3CA55543-0A05-44E9-A7C6-368D8C796E76Q30499197-AC1892D7-96DE-4423-8C32-47CA154331DBQ31007957-284195EC-FEF4-47D0-806A-5681EFE78F7DQ33293456-C6A63A92-5791-4442-9141-5F6CE3CEDDE3Q33332059-4153DB0A-3DBF-4894-BA16-44E5A3147EF7Q33533979-0ADDE82C-0733-4C47-9B4A-23088CBD5A89Q33889654-6F899751-AE6F-4C8C-99F0-43B00EDA140DQ33891197-61BC0C2E-F04C-4C23-AB43-D74FB422201AQ34241935-7515CEBA-EB67-48EA-A4BD-7D23D1B8E6A9Q34698815-38E289FC-2C23-4379-85E8-DA427085E483Q34776574-C4B91840-646E-4288-915D-07BA44F5D995Q35289072-F7510461-80D9-4916-87A8-ED3F32CE5028Q35537180-ED07A0B7-1FCA-4CA3-8890-AED68AEEBB3AQ35915297-ED814DC6-7CF6-4B75-973F-ED99207BBA11Q36383494-ABBA0C31-3124-4399-863F-2B6DDF98C4BBQ36484621-FFA20358-F06D-43B3-B454-5A6D20B30ACBQ37015727-631132A1-F8E5-415A-ACE0-244CF12F1651Q37093146-1C987A19-979D-4B2E-B068-4EC2CBA323FBQ37111059-F1E853CE-C5C5-4CED-A22D-37315622AA00Q37366202-B662C3D2-D613-418A-AB35-015AD9397C9FQ37575189-FC0E649B-6CB5-4DC9-9BDA-C46875013B70Q37602717-1AB6019B-7677-4987-BF20-F3FD5F15A95CQ37724878-7832A8AD-6886-4EC6-971F-45F6CF092D57Q37755150-F3E0E7A0-2205-47D9-A854-D9D3EC4C7AF3Q37942090-3DB5C282-315D-4988-A0B6-D313608F9B5EQ40062007-3F690F67-8F04-414F-BF74-9773C8AAD0BDQ40473727-94A25C43-67CA-4F9A-A055-D21F43BAF415Q41458695-A3E10423-D3A0-4511-BE43-7B0CF349668CQ41541842-EB24E96B-DBA8-42B6-9329-DAC328090048Q41858901-646A7D93-96C4-4811-BA3E-75ECD3EF840CQ41883096-AAAFD509-22E8-4582-983A-E9062E9415B6Q42249715-9E26A26E-5174-485D-80F3-A4770CB1DC5CQ43137450-F495AFC9-96CE-4CBA-AC9D-7C2744913D1FQ43721625-13509592-B4FC-4C5E-86FA-BCB7D258BE5BQ44724255-6897982F-EC80-4683-B0D7-5AE9CD305F46Q46853359-F06911DF-AF22-4C9D-95CB-D4CF0DAA9772Q50907573-7D6BBA6C-1990-4272-B1FA-9B536A6C8AEA
P2860
Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Determining tumor apoptosis an ...... cytokeratin 18 as a biomarker.
@ast
Determining tumor apoptosis an ...... cytokeratin 18 as a biomarker.
@en
type
label
Determining tumor apoptosis an ...... cytokeratin 18 as a biomarker.
@ast
Determining tumor apoptosis an ...... cytokeratin 18 as a biomarker.
@en
prefLabel
Determining tumor apoptosis an ...... cytokeratin 18 as a biomarker.
@ast
Determining tumor apoptosis an ...... cytokeratin 18 as a biomarker.
@en
P2093
P1433
P1476
Determining tumor apoptosis an ...... cytokeratin 18 as a biomarker.
@en
P2093
Aleksandra Mandic Havelka
Maria C Shoshan
Takayuki Ueno
P356
10.1016/J.CANLET.2004.06.032
P407
P50
P577
2004-10-01T00:00:00Z